Market capitalization | $155.76m |
Enterprise Value | $138.11m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.83 |
P/S ratio (TTM) P/S ratio | 8.83 |
P/B ratio (TTM) P/B ratio | 6.34 |
Sales growth (TTM) Sales growth | 754.68% |
Turnover (TTM) Turnover | $17.63m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
6 Analysts have issued a scPharmaceuticals, Inc. forecast:
6 Analysts have issued a scPharmaceuticals, Inc. forecast:
Dec '23 | |
Current assets | 93 93 |
Fixed assets | 1.54 1.54 |
Total assets | 94 94 |
Dec '23 | |
Equity | 37 37 |
Debt capital | 57 57 |
Total capital | 94 94 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Head office | United States |
CEO | John Tucker |
Employees | 136 |
Founded | 2013 |
Website | www.scpharmaceuticals.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.